Kalwinsky D K, Dahl G V, Mirro J, Look A T
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):887-9.
Reinduction therapy consisting of cyclophosphamide (250 mg/m2 orally daily for 4 days) followed by etoposide (250 mg/m2 iv daily for 3 days) was administered to 14 children with refractory or recurrent acute nonlymphocytic leukemia. Five complete remissions were achieved in eight patients who had relapsed in the bone marrow 1-27 months after cessation of initial therapy, which included anthracyclines, cytarabine, etoposide, and 5-azacitidine. Reinduction attempts were unsuccessful in patients who had failed to achieve an initial remission and in those whose relapses occurred while receiving therapy. Toxicity, including myelosuppression and mucositis, was within acceptable limits. This drug combination deserves further assessment in therapeutic protocols for patients with acute nonlymphocytic leukemia.
对14例难治性或复发性急性非淋巴细胞白血病患儿给予再诱导治疗，治疗方案为环磷酰胺（每日口服250mg/m²，共4天），随后给予依托泊苷（每日静脉注射250mg/m²，共3天）。8例在初始治疗（包括蒽环类药物、阿糖胞苷、依托泊苷和5-阿扎胞苷）停止后1 - 27个月骨髓复发的患者中有5例实现了完全缓解。初次诱导未缓解的患者以及在接受治疗期间复发的患者再诱导尝试未成功。包括骨髓抑制和粘膜炎在内的毒性在可接受范围内。这种药物组合值得在急性非淋巴细胞白血病患者的治疗方案中进一步评估。
